NCT00635674View on ClinicalTrials.gov

Effects of CPAP on Cardiovascular Risk in Obstructive Sleep Apnea (OSA) and Metabolic Syndrome

NACompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Obstructive Sleep ApneaMetabolic Syndrome
Interventions
DEVICE

CPAP device - REMstar Plus, Respironics, Murrysville, USA

continuous positive airway pressure device with heated humidification

Trial Locations (1)

041 90

Medical Faculty, PJ Safarik University, Košice

All Listed Sponsors
lead

Pavol Jozef Safarik University

OTHER

NCT00635674 - Effects of CPAP on Cardiovascular Risk in Obstructive Sleep Apnea (OSA) and Metabolic Syndrome | Biotech Hunter | Biotech Hunter